We are in an ever evolving world where the impact of the Biotech Therapeutic sector has been receiving much more attention. In the UK, the British Govt has recently passed new legislation regarding tax efficient investing into Knowledge Intensive (KI) funds, which will support these innovative science start-ups.
In this episode of o2h ChaiTime, on the back of HMRC’s approval of ‘the o2h Ventures ‘Human Health Knowledge Intensive Fund’ we discussed the importance of these government backed initiatives to support the much needed next wave of innovative businesses.
Following his training at the University of Glasgow Dr. Andrew joined the biotech BioFocus. After 6 years in industry he joined the DDU & worked 3 years on neglected disease research, then he began work developing the DDU’s first world disease programmes: The Innovative Targets Portfolio (ITP).
Mark has over twenty years experience in Financial services and prior to becoming Director General of the EIS Association, he was Head of Research and Development at Mazars, a leading UK financial planning firm.
Martin’s career in the City started as a healthcare analyst in 1987, working at Morgan Grenfell and then UBS. He joined HSBC in 1992, where he was Head of Global Pharmaceutical/Healthcare Equity Research. In 2005, he set up as a Life Sciences Analyst and Corporate Broker under the umbrella of Eden Financial Limited.